Initial Data Transfer Sample Clauses

Initial Data Transfer. (1) Within sixty (60) days after License Option Exercise, MacroGenics shall deliver to Takeda electronic copies (unless otherwise required by Applicable Law) of all Regulatory Materials relating to the Products in the Field in the Territory which are owned or Controlled by MacroGenics. Promptly after such transfer, but in any case within ten (10) Business Days, MacroGenics shall take all steps reasonably necessary to assign all INDs, Regulatory Applications and Regulatory Approvals to Takeda, including submitting to any applicable Regulatory Authority a letter or other necessary documentation (with copy to Takeda) notifying the Regulatory Authority of the assignment. (2) Within ninety (90) days after License Option Exercise, MacroGenics shall make available to Takeda separate electronic copies of all remaining Regulatory Documentation, including the study reports from all non-clinical trials and clinical trials, in each case, whether completed prior to the exercise of the License Option or then in-progress, that are owned or Controlled by MacroGenics (to the extent not previously provided to Takeda). (3) Notwithstanding Section 6.5(a)(1) and Section 6.5(a)(2), from time to time after License Option Exercise, to the extent not done so already, MacroGenics shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to Takeda, in whatever form Takeda may reasonably request, as soon as reasonably practicable after the earlier of the development, making, conception or reduction to practice, all Regulatory Documentation and other Information Controlled by MacroGenics, which in each case is reasonably necessary or useful for Takeda’s Exploitation of the Compounds and the Products, including copies or tangible embodiments thereof. For clarity, MacroGenics will have the right, unless otherwise required by Applicable Law, to retain original copies of the foregoing.

Initial Data Transfer. Within a reasonable time not to exceed […***…] following the Effective Date, Palatin shall disclose to AMAG all Palatin Know-How necessary or useful in connection with securing Regulatory Approval and Commercializing Products in the CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[…***…]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24B-2 PROMULGATED UNDER THE SECURITIES ACT OF 1934, AS AMENDED. Territory, together with such additional Palatin Know-How as AMAG may reasonably request, in each case to the extent developed by Palatin on or prior to the Effective Date, in either the format in which such Palatin Know-How then exists or in such other format as AMAG may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by AMAG).

Initial Data Transfer. Within a reasonable time not to exceed [ * ] following the Effective Date, Sangamo will disclose to Pfizer true, accurate and complete copies of all Licensed Know-How, in each case to the extent developed by Sangamo on or prior to the Effective Date and in such format as Pfizer may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by Pfizer).

Initial Data Transfer. Within a reasonable time not to exceed [***] following the Effective Date, Valneva will disclose to Pfizer true, accurate and complete copies of all Valneva Know-How, including all preclinical and Phase 1 data, in each case to the extent developed by Valneva on or prior to the Effective Date and in its current (electronic or other) format as Pfizer may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by Pfizer).

Initial Data Transfer. Within a reasonable time not to exceed […***…] following the Initial Payment Date (as hereafter defined), Palatin shall disclose to Fosun all Palatin Know-How necessary or useful in connection with securing Regulatory Approval and Commercializing Products in the Territory, together with such additional Palatin Know-How as Fosun may reasonably request, in each case to the extent developed by and Controlled by Palatin on or prior to the Effective Date, in either the format in which such Palatin Know-How then exists or in such other format as Fosun may reasonably request (including by download of digital files to a secure website or e-room designated by Fosun).

Initial Data Transfer. Within a reasonable time not to exceed [***] following the Effective Date and to the extent LimmaTech is allowed to do so under Applicable Law, LimmaTech will disclose to Valneva true, accurate and complete copies of all Development Data to the extent Controlled by LimmaTech on the Effective Date and in its current (electronic or other) format as Valneva may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by Valneva).

Initial Data Transfer. Within sixty (60) days after the Effective Date, Cell Genesys shall make available to Takeda copies of all Regulatory Materials of Cell Genesys generated as of the Effective Date and relating to the use of the Product (as defined in Section 1.69(a)) in the Field. Within ninety (90) days after execution of this Agreement, Cell Genesys shall deliver to Takeda copies of the study reports from Phase 1 Clinical Trials and Phase 2 Clinical Trials completed as of the Effective Date that are Controlled by Cell Genesys (to the extent not previously provided to Takeda), as such reports become available to Cell Genesys, and to the extent that they relate to the use of the Product in the Field.

Initial Data Transfer. As soon as practicable but not later than three (3) months after the Effective Date, AMAG shall provide Takeda (i) copies of all filings contained within the Regulatory Materials of AMAG generated as of the Effective Date and relating to the Product in the Field and relevant to the Licensed Territory, and (ii) access to the clinical databases and copies of the study reports from those clinical trials set forth on Schedule 5.1, including any updates to such databases and reports as such updates become available to AMAG, to the extent that they relate to the Product in the Field.

Initial Data Transfer. Within sixty (60) days of the Effective Date, CytRx shall make available to PDC in English and in writing for its use, CytRx Know-How in CytRx’s possession as of the Effective Date, including but not limited to the embodiments of such CytRx Know-How as set forth on the attached Schedule B. CytRx also agrees to disclose to PDC, upon execution of this Agreement CytRx’s pending United States Patent Applications identified in Schedule A of this Agreement.